Compare Adaptive Biotechnologies Corp (ADPT) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Domino's Pizza, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while Domino's Pizza, Inc. trades at $304.94 (market cap $10.42B). The key difference: Domino's Pizza, Inc. is far larger — about 3.1× Adaptive Biotechnologies Corp's market cap, and Domino's Pizza, Inc. pays a 2.54% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DPZ | |
|---|---|---|
Market Cap | $3.33B | $10.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $485.53 |
52-Week Low | $10.24 | $282.89 |
Enterprise Value | $3.19B | $15.32B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Domino's Pizza (DPZ) trades at $313.14, up 0.47% on the day, but remains near its 52-week low amid a bearish technical trend. The company reported mixed Q1 2026 earnings with an EPS miss of $4.13 vs. $4.27 expected, though revenue growth has been steady, reaching $4.94B in 2025. Analyst consensus is bullish with a $386.07 price target, but recent CEO transition and slowing same-store sales present near-term headwinds. Cash flow from operations remains strong at $792M in 2025, supporting dividends and buybacks.
DPZ offers value with a P/E of 17.6x and solid profitability (net margin 11.9%), but high debt levels and competitive pressures pose risks. The stock's 25% YTD decline creates a potential entry point for long-term investors, though execution under new leadership and consumer spending trends will be critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
